Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc.HEPA · Entity 8208 | Chief Financial Officer | May 18, 2021 | May 20, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hepion Pharmaceuticals, Inc.
Report date May 18, 2021 · Filed May 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2031-05-18 | Direct | 1,581,060 |
Reported balance
After 2021-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-18 · Grant · Acquired 1,200,000 · Balance 1,581,060 F1: Stock Options have been granted subject to stockholder approval of an increase in the shares of common stock issuable pursuant to the 2013 Equity Incentive Plan. F2: 400,000 of the stock options vest on 5/18/2022 and the remainder vests monthly in equal amounts over 24 months. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock Options have been granted subject to stockholder approval of an increase in the shares of common stock issuable pursuant to the 2013 Equity Incentive Plan.
F2: 400,000 of the stock options vest on 5/18/2022 and the remainder vests monthly in equal amounts over 24 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2021 Filed May 20, 2021 16:35 UTC | Hepion Pharmaceuticals, Inc. HEPA · Entity 8208 | GrantStock Options · Derivative | 1,200,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001104659-21-069938 · tm2117144-4_4seq1.xml · derivative · entry 1 Cavan John T · CIK 0001503738 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,581,060 Underlying: Common Stock · 1,200,000 shares Expires 2031-05-18 F1 · security: Stock Options have been granted subject to stockholder approval of an increase in the shares of common stock issuable pursuant to the 2013 Equity Incentive Plan. F2 · derivative.exercise_date: 400,000 of the stock options vest on 5/18/2022 and the remainder vests monthly in equal amounts over 24 months. Read SEC document |
| February 18, 2021 Filed Feb 18, 2021 16:05 UTC | Hepion Pharmaceuticals, Inc. HEPA · Entity 8208 | PurchaseCommon Stock | 10,000 | $2.00 | $20,000.00 |
DisclosureSEC source: 0001104659-21-025196 · tm217063-1_4seq1.xml · nonDerivative · entry 1 Cavan John T · CIK 0001503738 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,800 Read SEC document |
| November 25, 2020 Filed Nov 30, 2020 16:53 UTC | Hepion Pharmaceuticals, Inc. HEPA · Entity 8208 | PurchaseCommon Stock | 4,500 | $1.62 | $7,290.00 |
DisclosureSEC source: 0001104659-20-130531 · a4.xml · nonDerivative · entry 1 Cavan John T · CIK 0001503738 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,800 Read SEC document |
| August 19, 2020 Filed Aug 21, 2020 16:15 UTC | Hepion Pharmaceuticals, Inc. HEPA · Entity 8208 | GrantStock Options · Derivative | 160,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001104659-20-097591 · a4.xml · derivative · entry 1 Cavan John T · CIK 0001503738 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 381,060 Underlying: Common Stock · 160,000 shares Expires 2030-08-19 F1 · derivative.exercise_date: 53,333 of the stock options vest on 8/19/2021 and the remainder vests monthly in equal amounts over 24 months. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 16:13 UTC | Hepion Pharmaceuticals, Inc. HEPA · Entity 8208 | GrantStock Options · Derivative | 215,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001104659-20-044168 · a4.xml · derivative · entry 1 Cavan John T · CIK 0001503738 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,059 Underlying: Common Stock · 215,000 shares Expires 2030-04-03 F1 · derivative.exercise_date: 71,667 of the stock options vest on 4/3/2021 and the remainder vests monthly in equal amounts over 24 months. Read SEC document |
| July 24, 2019 Filed Jul 25, 2019 16:16 UTC | Hepion Pharmaceuticals, Inc. HEPA · Entity 8208 | GrantStock Options · Derivative | 5,820 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001104659-19-041851 · a4.xml · derivative · entry 1 Cavan John T · CIK 0001503738 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,059 Underlying: Common Stock · 5,820 shares Expires 2029-07-24 F1 · derivative.exercise_date: Options vest in three installments as follows: 1,940 options shall vest on each of July 24, 2020, 2021 and 2022. Read SEC document |
| July 03, 2018 Filed Jul 3, 2018 14:17 UTC | Hepion Pharmaceuticals, Inc. CTRV · Entity 8208 | PurchaseWarrants · Derivative | 8,625 | $1,000.00 Strike: $1.55 | $8,625,000.00 |
DisclosureSEC source: 0001104659-18-043797 · a4.xml · derivative · entry 2 Cavan John T · CIK 0001503738 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,625 Underlying: Common Stock · 8,625 shares Expires 2023-07-03 F3 · price: Shares of Series C Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series C Convertible Preferred Stock and 575 Warrants Read SEC document |
| July 03, 2018 Filed Jul 3, 2018 14:17 UTC | Hepion Pharmaceuticals, Inc. CTRV · Entity 8208 | PurchaseSeries C Convertible Preferred Stock · Derivative | 15 | $1,000.00 Strike: $1.55 | $15,000.00 |
DisclosureSEC source: 0001104659-18-043797 · a4.xml · derivative · entry 1 Cavan John T · CIK 0001503738 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15 Underlying: Common Stock · 9,678 shares Expires not disclosed F1 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock is convertible into the number of shares of Common Stock equal to the stated value of $1,000 divided by $1.55. F3 · price: Shares of Series C Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series C Convertible Preferred Stock and 575 Warrants F2 · derivative.expiration_date: Shares of Series C Convertible Preferred Stock do not expire. Read SEC document |
| January 03, 2018 Filed Jan 5, 2018 13:09 UTC | Hepion Pharmaceuticals, Inc. CTRV · Entity 8208 | GrantCommon Stock | 101,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-000925 · a4.xml · nonDerivative · entry 1 Cavan John T · CIK 0001503738 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,947 F1 · price: The reported item represents an award of restricted stock pursuant to the Company's 2013 Equity Incentive Plan. All of the shares vested upon grant. Such shares were issued in lieu of a cash bonus to the reporting person. Read SEC document |
| July 20, 2017 Filed Jul 21, 2017 16:01 UTC | Hepion Pharmaceuticals, Inc. CTRV · Entity 8208 | GrantStock Options · Derivative | 15,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001104659-17-046277 · a4.xml · derivative · entry 1 Cavan John T · CIK 0001503738 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,688 Underlying: Common Stock · 15,000 shares Expires 2027-07-20 F1 · derivative.exercise_date: Options vest in three installments as follows: 5,000 vest on each of July 20, 2018, 2019 and 2020. Read SEC document |
| July 06, 2017 Filed Jul 7, 2017 17:01 UTC | Hepion Pharmaceuticals, Inc. CTRV · Entity 8208 | GrantCommon Stock | 46,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-044101 · a4.xml · nonDerivative · entry 1 Cavan John T · CIK 0001503738 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,726 F1 · price: The reported item represents an award of restricted stock pursuant to the Company's 2013 Equity Incentive Plan. All of the shares vested upon grant. Such shares were issued in lieu of a cash bonus to the reporting person. Read SEC document |
| June 20, 2017 Filed Jun 22, 2017 09:00 UTC | Hepion Pharmaceuticals, Inc. CTRV · Entity 8208 | PurchaseCommon Stock | 20,000 | $0.65 | $13,000.00 |
DisclosureSEC source: 0001104659-17-040822 · a4.xml · nonDerivative · entry 1 Cavan John T · CIK 0001503738 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.